Oral antidiabetic drugs: An overview

Diabetic Medicine

Volumn 13, Issue SUPPL. 6, 1996, Pages

  Melander, A ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acarbose; Antidiabetic agents; Biguanides; Combination therapy; Sulphonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

CONFERENCE PAPER; DIARRHEA; DIET THERAPY; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0029792628     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/dme.1996.13.s6.143     Document Type: Conference Paper

References (28)

1. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med 1989; 321: 337-343.
2. Simonson DC, Rossetti L, Giarccari A, et al. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, 1st edn. Oxford: Alden Press, 1992: 635-667.
3. Eriksson K-F, Lindgärde F. Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991; 34: 891-898.
4. Sartor G, Scherstén B, Carlström S, et al. Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet-regulation. Diabetes 1980; 29: 41-49.
5. Bitzén P-O, Melander A, Scherstén B, et al. The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia. Eur J Clin Pharmacol 1988; 35: 31-37.
6. Bitzén P-O, Melander A, Scherstén B, et al. Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 1992; 42: 77-83.
7. Lebovitz HE, Melander A. Sulphonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. 1st edn. Oxford: Alden Press, 1992: 745-772.
8. Sartor G, Ursing D, Nilsson-Ehle P, et al. Lack of primary effect of sulfonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion. Eur J Clin Pharmacol 1987; 33: 279-282.
9. Ferner R, Rawlins MD, Alberti KGMM. Impaired β-cell responses improve when fasting blood glucose concentration is reduced in non-insulin dependent diabetes. Q J Med 1988; New Series 66 (259): 137-146.
10. Wåhlin-Boll E, Sartor G, Melander A, et al. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1982; 222: 21-25.
11. Karam JH, Sanz N, Salamon E, et al. Selective unresponsiveness of pancreatic β-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986; 35: 1314-1320.
12. Stenman S, Melander A, Groop P-H, et al. What is the benefit of increasing the sulphonylurea dose? Annals Int Med 1993; 118: 169-172.
13. Wåhlin-Boll E, Groop L, Karhumaa S, et al. Therapeutic equivalence of once- and thrice-daily glipizide. Eur J Clin Pharmacol 1986; 31: 95-99.
14. Wåhlin-Boll E, Almér L-O, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in Type 2 diabetics. Clin Pharmacokinet 1982; 7: 363-372.
15. Wåhlin-Boll E, Melander A, Sartor G, et al. Influence of food intake on the absorption and effect of glipizide in diabetics and healthy subjects. Eur J Clin Pharmacol 1980; 18: 279-283.
16. Groop L, DeFronzo R, Luzi L, et al. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet 1989; ii: 129-130.
17. Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991; 14: 724-727.
18. Hermann LS, Scherstén B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabetic Med 1994; 11: 953-960.
19. Persson G. Cardiovascular complications in diabetics and subjects with reduced glucose tolerance. Acta Med Scand 1977; Suppl 605.
20. Knowler WC, Sartor G, Scherstén B. Effects of glucose tolerance and treatment of abnormal tolerance on mortality in Malmöhus County, Sweden (Abstract). Diabetologia 1987; 30: 541A.
21. Keen H, Jarret RJ, Fuller JH. Tolbutamide and arterial disease in borderline diabetics. In: Malaisse WJ, Pirart J, eds. Proceedings VIII Congress of the International Diabetes Federation. Amsterdam: Excerpta Medica 1973: 588-602.
22. Stowers J. Treatment of chemical diabetes with chlorpropamide and the associated mortality. Adv Metab Dis 1973; 2(suppl 2): 549-555.
23. Wolffenbuttel BHR, Nijst L, Sels JPJE, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-116.
24. Shinkai H, Sato Y. Hypoglycaemic action of phenylalanine derivatives. In: Bailey CJ, Flatt PR, eds. New Antidiabetic Drugs. London: Smith-Gordon, 1990: 249-254.
25. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. 1st edn. Oxford: Alden Press, 1992: 773-795.
26. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 1994; 331: 1188-1193.
27. Buchanan DR, Collier A, Rodrigues E, et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. Eur J Clin Pharmacol 1988; 34: 51-53.
28. Hermann LS, Scherstén B, Bitzén P-O, et al. Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations: A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.